

REMARKS

In the November 5, 2002 Office Action, the Examiner maintained the requirement for restriction and identified a subgenera of compounds within the genus of claim 1 which the Examiner considered "patentably distinct" (see page 6, line 9, of the November 5, 2002 Office Action). However, the Examiner stated that if the subject claims were to be presented drawn solely to the elected subject matter, then the withdrawn method claims, which depend from or otherwise include all the limitations of the allowable product claims, would be rejoined.

In response, applicants have in the above amendments cancelled all of the non-elected subject matter from the claims directed to compounds *per se* and have rewritten the method claims all in a dependent form. Hence, the method claims, as amended above, all are of a scope corresponding to the subgenera of "patentably distinct" compounds identified by the Examiner in the November 5, 2002 Office Action. Applicants, in the above amendments, have also rewritten the pharmaceutical composition claims to a scope corresponding to the "patentably distinct" subgenera of compounds identified by the Examiner. Applicants kindly request that the Examiner, since kindly permitting claims directed to methods, likewise permit the claims directed to pharmaceutical compositions, so long as said claims are corresponding to the scope of compounds examined by the Examiner.


Applicants make all of the above amendments simply to advance the prosecution of the subject application. Applicants reserve the right to file one or more continuation or divisional applications directed to any non-elected, cancelled subject matter.

If a Telephone Interview would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney respectfully invites the Examiner to telephone her at the number provided.

No fee, other than the fee for the three month extension of time the payment of which is authorized in the Petition filed herewith and the fee for the submission of the Information Disclosure Statement the payment of which is authorized in said Information Disclosure Statement, is believed necessary in connection with filing this Amendment. However, if any other fee is determined necessary in connection with filing this Amendment, the Commissioner is authorized to charge such fee to Deposit Account No. 16-1445.

Date: May 5, 2003

Respectfully submitted,



Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733 -6380